Sanofi Crowned 'Top Employer China 2024' for the Fourth Consecutive Year

ShanghaiJanuary 18, 2024PR Newswire -- Today, the "Top Employer China 2024" list awarded by the Top Employers Institute was officially announced. Sanofi ranked first due to its outstanding performance in corporate culture, talent strategy, diversity development, and employee training, becoming the only company in China in nearly a decade to top the list for four consecutive years. This is also the seventh consecutive year that Sanofi has been certified as a "Top Employer in China."

Sanofi Ranks First in “China Outstanding Employer” for the Fourth Consecutive Year

Sanofi Greater China President, Shuang Shi:

"I am extremely proud that Sanofi has been crowned the top position on the ‘China Outstanding Employer’ list for four consecutive years, a full affirmation of Sanofi’s continuous investment in talent development. Sanofi Global and China's all-out winning strategy has entered a new chapter, with a comprehensive and effective talent strategy being the key driving force supporting Sanofi’s accelerated innovation and ambition to become a leader in the immunology field. Upholding the mission of ‘Pursuing scientific miracles to rejuvenate the brilliance of life,’ we will further stimulate the strong momentum of local talent development in China, and jointly contribute to the early realization of the ‘Healthy China 2030’ blueprint."

Fei Li, Head of Talent and Organization Culture, Greater China Region, Sanofi:

"Sanofi Ranks First in ‘China Outstanding Employer’ List for the Fourth Time, a High Recognition of Our Long-Term Efforts and Practices in Talent Development. In the Future, We Will Continue to Build a Trustworthy Corporate Talent Cultivation Environment, Continuously Create a More Diverse, Equitable, and Inclusive Workplace, Support the Two-Way Sustainable Development of the Company and Employees, and Inject Strong Talent Momentum into the High-Quality Development of China's Healthcare Industry."

Embarking on a New Chapter of Full-Power Victory Achieving a Win-Win Situation for Both the Company and Its Employees

Currently, the world is unfolding in an unprecedented manner, and China's healthcare industry is facing boundless challenges and opportunities. To further deepen its "Commitment to China," Sanofi has established a new "China Ambition" to solidly promote the company’s growth in the Chinese market. This ambition supports high-quality development of corporate talent through business growth, fostering a fertile ground for employee development, and ensuring the stability, longevity, and flexibility of local talent cultivation, thereby promoting high-quality development in China's healthcare industry.

Rooted in the Chinese market for four decades, Sanofi has continuously pursued scientific miracles, committed to transforming scientific innovation into healthcare solutions and promoting Sanofi's "China Solution" to benefit more Chinese patients as soon as possible. Today, China has become Sanofi's second-largest global market, with business scopes ranging from prevention to treatment, covering multiple fields such as general medicines, specialty medicines, vaccines, and consumer healthcare. In 2023, Sanofi received approval from China’s National Medical Products Administration (NMPA) for 12 innovative products and indications, bringing new treatment options to more patients and earnestly fulfilling its "China Promise."

In 2024, Sanofi ushers into a new chapter of its all-out winning strategy, focusing on the biopharmaceutical field and aspiring to become an industry leader in immunology. The company is committed to the research and development of First-in-Class and Best-in-Class pipelines, driving high-quality development within the industry. Moving forward, Sanofi will continue to deepen its localization strategy in China, consistently launching innovative pipelines tailored for the Chinese market. Among approximately 90 global projects under development, 61 drugs are being developed simultaneously in China, significantly shortening the time for future new drug launches in the country and accelerating the availability of innovative products and solutions for Chinese patients.

Workplace Diversity Without Limits Pursuing非凡 New Proposition

In the process of further advancing the core strategy of "Go-for-Win," Sanofi firmly believes that a leading talent development strategy is key to building a competitive advantage for the company. The "Extraordinary Growth" talent strategy practiced by Sanofi not only provides employees with a diverse, fair, and inclusive work environment and development platform—including establishing diversified employee clubs, offering 98 days of gender-equal paid parental leave, and setting up flexible working mechanisms—but also focuses on providing support and care for all employees affected by serious illnesses. At the same time, Sanofi offers unlimited career development opportunities for employees, including an internal transfer mechanism without tenure restrictions or managerial approval, the Sanofi Global Diverse Gig Program, international talent exchange programs, and other broad, unrestricted career development paths, empowering employees to keep pace with industry changes and move forward steadily amidst the waves of transformation.

In response to an increasingly diversified and highly competitive professional environment, while pursuing personal development and career advancement, Sanofi has a distinctive answer to how to empower young employees with positive beliefs and confident steps toward a broader life. This year, Sanofi announced a brand-new Employee Value Proposition: "Pursue Growth, Explore the Extraordinary," encouraging every young employee to "keep exploring, seek change, act with integrity, and create miracles." The company is committed to igniting employees' passion, enabling everyone to become the best version of themselves in an inclusive work environment, achieving excellence and growth.

For many years, Sanofi has forged ahead amidst challenges, maintaining an upward momentum in corporate development to create a sustainable work environment for its employees. Based on a leading talent strategy, the company continuously strengthens its talent development and training systems in all aspects, inspiring employees to explore broader personal growth opportunities. Sanofi will continue to increase investment and improve its talent pipeline construction, promoting corporate innovation to benefit more patients in China. While driving high-quality development in China's healthcare industry, it actively addresses the growing and unmet health needs of Chinese patients, reaffirming its steadfast commitment to the Chinese market and patients.